Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
innovation tags : Phase 3 save search
Innovent Releases Results of a Phase 3 Clinical Study of IBI306 (PCSK-9 inhibitor) in Chinese Patients with Heterozygous Familial Hypercholesterolemia at the American College of Cardiology Annual Congress 2022
Published: 2022-04-04 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.03%
H: 0.76%
C: -0.45%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.71%
H: 1.47%
C: 0.5%
ibi306 chinese cardiology results phase 3 hypercholesterolemia
Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer
Published: 2022-03-23 (Crawled : 12:00) - novocure.com
NVCR | $12.35 2.45% 2.39% 1.1M
|
Health Technology
|
| O: -2.16%
H: 2.52%
C: -0.91%
cancer phase 3 ovarian cancer
INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.
Published: 2021-11-09 (Crawled : 13:15) - inovio.com
INO | $10.1 -2.6% -2.67% 250K
|
Health Technology
|
| O: 4.79%
H: 7.71%
C: 0.71%
covid fda vaccine phase 3 ino-4800
INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India
Published: 2021-11-03 (Crawled : 12:15) - inovio.com
INO | $10.1 -2.6% -2.67% 250K
|
Health Technology
|
| O: 2.35%
H: 0.81%
C: 0.67%
covid india vaccine phase 3 trial ino-4800
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer
Published: 2021-10-28 (Crawled : 12:00) - biospace.com/
NVCR | $12.35 2.45% 2.39% 1.1M
|
Health Technology
|
| O: -4.1%
H: 0.0%
C: -4.24%
cancer phase 3 ovarian cancer trial enroll
Innovent Announces ORIENT-31, a Phase 3 Study of Sintilimab in Patients with EGFR-Mutated Nonsquamous Non-Small Cell Lung Cancer with Prior EGFR-TKI Treatment, Has Met Primary Endpoint
Published: 2021-10-18 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.14%
H: 1.98%
C: 0.43%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: -1.45%
treatment lung cancer cancer phase 3
INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization
Published: 2021-10-11 (Crawled : 12:00) - prnewswire.com
INO | $10.1 -2.6% -2.67% 250K
|
Health Technology
|
| O: -1.21%
H: 5.95%
C: 3.82%
covid vaccine phase 3 authorized ino-4800
Innovent Releases Interim Analysis Results of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in the Phase 3 ORIENT-16 Study at ESMO Congress 2021
Published: 2021-09-18 (Crawled : 00:20) - prnewswire.com
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
| Email alert
Add to watchlist
treatment therapy results phase 3
Innovent Releases Interim Analysis Results of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma in the Phase 3 ORIENT-15 Study at ESMO Congress 2021
Published: 2021-09-18 (Crawled : 00:20) - prnewswire.com
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
| Email alert
Add to watchlist
treatment therapy results phase 3 cell carcinoma
Innovent Announces Sintilimab in Combination with Chemotherapy Meets the Primary Endpoint of Overall Survival in the Phase 3 ORIENT-16 Study
Published: 2021-08-16 (Crawled : 13:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.33%
H: 2.03%
C: 1.91%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.53%
H: 0.72%
C: 0.68%
therapy phase 3
Innovent Announces Sintilimab in Combination with Chemotherapy Meets the Primary Endpoint of Overall Survival in the Phase 3 ORIENT-16 Study for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Published: 2021-08-16 (Crawled : 00:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.33%
H: 2.03%
C: 1.91%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.53%
H: 0.72%
C: 0.68%
treatment therapy phase 3
Innovent Announces IBI306 (anti-PCSK-9 antibody) Meets the Primary Endpoint in a Phase 3 Clinical Study for Chinese Heterozygous Familial Hypercholesterolemia
Published: 2021-08-12 (Crawled : 00:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.34%
H: 0.51%
C: 0.1%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.55%
H: 0.2%
C: -0.55%
chinese antibody phase 3 hypercholesterolemia
Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.18%
H: 2.77%
C: 1.95%
chinese solid tumors phase 1 results phase 3 phase 2
Innovent Announces First Patient Dosed in China in the Global Phase 3 Clinical Trial of Pemigatinib as the First-line Treatment of Unresectable or Metastatic Cholangiocarcinoma
Published: 2021-05-25 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.2%
H: 0.21%
C: -1.1%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.06%
H: 0.98%
C: -0.34%
treatment china phase 3 trial
Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021
Published: 2021-04-13 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.35%
H: 1.36%
C: 0.75%
treatment lung cancer injection results cancer phase 3
Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021
Published: 2021-04-12 (Crawled : 01:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.57%
H: 0.28%
C: -0.88%
treatment lung cancer injection results cancer phase 3
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.